Real‐world treatment persistence of four commonly prescribed biologic therapies for moderate to severe psoriasis in Australia
Australasian Journal of Dermatology · 2023-11 · 64 (4) · 504-513
DOI: 10.1111/ajd.14153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Australasian Journal of Dermatology, online erschienen am 13.09.2023. Verfasst von John Sullivan und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Sutherland Hospital, Caringbah, New South Wales, Australia. Hauptthemen laut MEDLINE: Psoriasis, Biological Products. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen-Cilag Pty Ltd.
Abstract (Originalsprache)
Background/Objectives Australian data comparing biologic treatments for moderate to severe chronic plaque psoriasis are lacking. We compared persistence on therapy across four biologic therapies (adalimumab, guselkumab, secukinumab and ustekinumab) used to treat chronic plaque psoriasis. The impact of prior biologic use on persistence was also investigated.
Methods
This retrospective cohort analysis of the Pharmaceutical Benefits Scheme (PBS) 10% sample included data from adult patients prescribed ≥1 biologic of interest by a dermatologist from 1 September 2015 to 31 December 2021. Persistence was defined as continued use until 180 days without a prescription. The index date was the date of the first claim of the biologic. Persistence was evaluated using Kaplan–Meier methods, log‐rank tests, adjusted analyses using Cox's regressions, and propensity score matching.
Results
In total, 878 patients, with 1131 index prescriptions, were included. Guselkumab median persistence was not reached in the study period (PBS listed from February 2019). In the adjusted analysis, persistence to guselkumab was significantly greater than to adalimumab ( n = 105; median 16 months, HR 2.71 (95% CI 1.94–3.8), p < 0.001), ustekinumab ( n = 336; median 19 months, HR 2.91 (95% CI 2.22–3.82), p < 0.001) and secukinumab ( n = 305; median 30 months, HR 1.8 (95% CI 1.36–2.38), p < 0.001). Bio‐naïve patients had longer persistence on treatment than bio‐experienced patients.
Conclusions
The nationally representative PBS dataset can provide real‐world insights into the persistence on biologic therapies for psoriasis in Australia, where eligibility criteria for reimbursed treatment are stringent. Persistence is an indirect marker of sustained treatment effectiveness and tolerability. Both unadjusted and adjusted analyses found longer persistence for guselkumab compared to adalimumab, secukinumab or ustekinumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Sutherland Hospital, Caringbah, New South Wales, Australia.
- University of NSW, Kensington, New South Wales, Australia.
- Kingsway Dermatology & Aesthetics, Miranda, New South Wales, Australia.
- Janssen Australia, Macquarie Park, New South Wales, Australia.
- St Vincent's Hospital, Melbourne, Victoria, Australia.
- The University of Melbourne, Melbourne, Victoria, Australia.
Förderung
- Janssen-Cilag Pty Ltd
Zitieren
APA
Sullivan, J., Hannam, S., Puig, A., Maranta, D., McGeachie, A. B., & Baker, C. (2023). Real‐world treatment persistence of four commonly prescribed biologic therapies for moderate to severe psoriasis in Australia. Australasian Journal of Dermatology, 64(4), 504-513. https://doi.org/10.1111/ajd.14153
Vancouver
Sullivan J, Hannam S, Puig A, Maranta D, McGeachie AB, Baker C. Real‐world treatment persistence of four commonly prescribed biologic therapies for moderate to severe psoriasis in Australia. Australasian Journal of Dermatology. 2023;64(4):504-513. doi:10.1111/ajd.14153
BibTeX
@article{Sullivan2023,
author = {Sullivan, John and Hannam, Sarah and Puig, Andrea and Maranta, Debra and McGeachie, Andrew B and Baker, Christopher},
title = {Real‐world treatment persistence of four commonly prescribed biologic therapies for moderate to severe psoriasis in Australia},
journal = {Australasian Journal of Dermatology},
year = {2023},
volume = {64},
number = {4},
pages = {504--513},
doi = {10.1111/ajd.14153}
}
EUVIMED